Stock Price Forecast

March 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading TG Therapeutics Inc chart...

About the Company

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".

$2M

Total Revenue

276

Employees

$2B

Market Capitalization

246.27

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $TGTX News

Q4 2023 TG Therapeutics Inc Earnings Call

19d ago, source: Yahoo Finance

Jenna Bosco; SVP, Corporate Communications; TG Therapeutics, Inc. Michael Weiss; President & CEO; TG Therapeutics, Inc. Adam Waldman; Chief Commercialization Officer ...

TG Therapeutics Inc TGTX

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

20d ago, source: Business Insider

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office ...

TG Therapeutics: Q4 Earnings Snapshot

19d ago, source: The Washington Post

MORRISVILLE, N.Y. — MORRISVILLE, N.Y. — TG Therapeutics Inc. (TGTX) on Wednesday reported a loss of $14.4 million in its fourth quarter. On a per-share basis, the Morrisville, New York-based ...

TG Therapeutics Announces European Launch of BRIUMVI® (ublituximab-xiiy)

20d ago, source: ADVFN

TG Therapeutics, Inc. (NASDAQ: TGTX) (TG Therapeutics) today announced that its ex-US partner, Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the ...

TG Therapeutics, Inc. (TGTX) Q4 2023 Earnings Call Transcript

19d ago, source: Seeking Alpha

Greetings, and welcome to the TG Therapeutics Fourth Quarter and Year-End 2023 Financial Results and Business Update Call. At this time, all participants are on a listen-only mode. A brief ...

TG Therapeutics, Inc.: TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI (ublituximab-xiiy)

20d ago, source: Finanznachrichten

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (TG) today announced the issuance of three additional patents by the United States Patent and Trademark Office ...

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript

19d ago, source: Yahoo Finance

TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2023 Earnings Call Transcript February 28, 2024 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.12.

TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy)

19d ago, source: ADVFN

TGTX TG Therapeutics Inc TG Therapeutics Announces Issuance of Additional Patents for BRIUMVI® (ublituximab-xiiy) NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...